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Abstract
Background: Focal and segmental glomerulosclerosis (FSGS) is the most common histologic pattern of renal injury seen in
adults with idiopathic proteinuria. Homozygous or compound heterozygous mutations in the podocin gene NPHS2 are found in
10–30% of pediatric cases of steroid resistant nephrosis and/or FSGS.
Methods: We studied the spectrum of genetic variation in 371 individuals with predominantly late onset FSGS (mean age of
onset 25 years) by analysis of DNA samples.
Results: We identified 15 non-synonymous alleles that changed the amino acid sequence in 63 of the subjects screened (17%).
Eight of these (p.R138Q, p.V180M, p.R229Q, p.E237Q, p.A242V, p.A284V, p.L327F and the frameshift 855–856 delAA) are
alleles previously reported to cause FSGS in either the homozygous or compound heterozygous states, while the remaining 7
(p.R10T, p.V127W, p.Q215X, p.T232I, p.L270F, p.L312V and the frameshift 397delA) are novel alleles that have not been
demonstrated previously. Twelve individuals of the 371 (3.2%) screened had two likely disease-causing NPHS2 alleles, present
in either a homozygous or compound heterozygous state. We genotyped the two most common of the non-synonymous NPHS2
alleles (p.A242V and p.R229Q) identified by resequencing in participants from the Nurses' Health Study and also genotyped
p.R229Q in 3 diabetic cohorts. We found that the presence of either of these variants does not significantly alter the risk of
albuminuria in the Nurses' Health participants, nor does p.R229Q associate with "diabetic nephropathy".
Conclusion: NPHS2 mutations are a rare cause of FSGS in adults. The most common non-synonymous NPHS2 variants,
p.R229Q and p.A242V, do not appear to alter the risk of proteinuria in the general population nor does p.R229Q associate with
measures of kidney dysfunction in diabetic individuals. Our results help clarify the frequency of FSGS-causing NPHS2 mutations
in adults and broaden our understanding of the spectrum of NPHS2 mutations that lead to human disease.
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Focal and segmental glomerulosclerosis (FSGS) is now the
most common histologic pattern of injury seen in adults
with primary glomerular disease [1]. Rather than a single
disease entity, FSGS describes a pattern of injury seen in
kidney damage secondary to a number of identifiable pri-
mary causes but also seen as an idiopathic, isolated find-
ing. Over the past decade, human genetic studies have
confirmed the heterogeneity of the underlying biological
cause of this histologic pattern. Heterozygosity for muta-
tions in ACTN4, TRPC6, and CD2AP cause rare forms of
steroid resistant FSGS [2-5]. Mutations in both NPHS2
(podocin) alleles also cause steroid resistant FSGS [6] and
are a much more common cause of FSGS than mutations
in other genes identified to date [7]. Podocin mutations
appear to cause 10–30% of childhood steroid resistant
nephrotic syndrome [8]. Although genetically distinct
forms of FSGS may follow different patterns of inherit-
ance, the pattern can be difficult to identify, particularly in
small families.
The clinical utility of genetic testing in the evaluation of
FSGS and nephrotic syndrome in adults remains unclear.
He et al found disease-segregating NPHS2 mutations in
only 1 of 87 FSGS subjects analyzed [9]. McKenzie et al
have suggested that homozygous or compound hetero-
zygous mutations in NPHS2 are very rare causes of spo-
radic, adult onset FSGS. They also found that
heterozygotes for R138Q are more common in cases with
FSGS than controls without the disease and reported that
a common haplotype in NPHS2 modifies disease risk in
African Americans but not European Americans [10].
Kidney biopsies are generally performed late in the evalu-
ation of a nephrotic child who does not respond to ster-
oids. Early identification of unambiguous disease-causing
mutations in both NPHS2 alleles could lead to avoidance
of prolonged glucocorticoid therapy and perhaps the need
for kidney biopsy in these patients. The clinical utility of
NPHS2 mutation analysis is much less clear in adults as
there exists a broader span of underlying etiologies in the
differential diagnosis in this age group and the histologic
lesions underlying nephrotic and subnephrotic proteinu-
ria overlap considerably. Here, we performed mutational
analysis of NPHS2 in a large group of probands with FSGS
to define the contribution of NPHS2 to late-onset disease.
In addition, we genotyped two relatively common non-
synonymous variants (cSNPs) in several sample sets to
assess the possible contribution of these variants to albu-
minuria in both the general adult population and among
diabetics, a group at high risk for the development of pro-
teinuric kidney disease.
Methods
Patients
Three hundred and seventy-one unrelated individuals
diagnosed with FSGS were studied. Of these, 122 (33%)
had at least one affected relative, while the remaining 249
(67%) were sporadic cases without a family history. Most
of these samples were ascertained after referral by a neph-
rologist caring for the subject and one or more family
members.
Two hundred (54%) of the subjects were Caucasian. The
remaining 171 were either African American (n = 68,
18.2%), Hispanic (n = 26, 7%), Asian (n = 6, 1.6%),
American Indian (n = 1, 0.2%) or of unreported ethnicity
(n = 70, 19%). Families and sporadic cases with radio-
logic, clinical or histopathologic findings consistent with
secondary forms of FSGS were excluded from the analysis.
The median age of onset of disease in the subjects studied
was 25 years (range 0.25-to-65 years of age). The median
age of onset of FSGS in the familial cases was 16 years
(range 1.20-to 50 years of age), while that of sporadic
patients was 26 years (range 1.25-to-69 years).
Nurses' Health study participants and type 1 and type 2 
diabetic patients
We genotyped samples from women enrolled in the
Nurses' Health Study I or II [11]. The Nurses' Health Study
(NHS) samples are large prospective cohorts of female
registered nurses. We also genotyped 1988 samples from
three distinct study groups, the University of Utah diabe-
tes study, the Genetics of Kidney Disease in Diabetes study
(GoKinD), and Australian endocrine diabetics. University
of Utah diabetes study: n = 280; 41 type 1 diabetic indi-
viduals and 239 with type 2 diabetes. Twenty patients
(49%) with type 1 diabetes and 89 patients (37%) with
type 2 diabetes had end-stage renal disease. Diabetic
patients without end-stage renal disease were used as con-
trols (21/41, 51% of type 1 diabetics; 150/239, 63% of
type 2 diabetics). Median age of type 2 diabetic cases was
22 years, and controls with type 2 diabetes was 19 years.
The median age of the type 1 diabetic cases and controls
was not available). Genetics of Kidney Disease in Diabetes
(GoKinD) study group: n = 1,279; 455 "case" samples
have end-stage renal disease and 824 who do not have
end-stage renal disease were used as "control" subjects. All
GoKinD subjects have long-standing (10+ years) of type 1
diabetes. Median age of the cases was 44, and median age
of controls was 40 years. Australian endocrine diabetes
group: n = 429; 67 type 1 diabetic subjects and 362 with
type 2 disease. Fifty-one of the type 1 diabetics had an uri-
nary albumin excretion rate (AER) <20 μg/min, 10 had an
AER between 20 μg/min and 200 μg/min, and the remain-
ing 6 had an AER >20 μg/min). Two hundred and twenty-
eight of the type 2 diabetics had an AER<20 μg/min, 83
had an AER between 20 μg/min and 200 μg/min, and thePage 2 of 10
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the type 1 microalbuminurics was 55 years, that of mac-
roalbuminurics was also 55 years and normoalbuminu-
rics was 53 years. The median age of the type 2 diabetics
with microalbuminuria was 67 years, that of macroalbu-
minurics was 68 years and normoalbuminurics was 70
years.
Informed Consent
Studies were performed in accordance with human sub-
ject protocols approved by the human research commit-
tees at each of the institutions.
Genetic analyses
NPHS2 sequence analysis
Genomic DNA was extracted from peripheral blood cells
using the QIAmp DNA blood kit (QIAGEN Inc., Valencia,
California, USA). Total genomic DNA (20–25 ng) was
amplified using primers designed from the analysis of the
available genomic sequence (Homo sapiens chromosome 1
BAC clone RP11-545A16, GeneBank accession number
AL160286). An ABI 3730xl DNA analyzer was used for
sequence analysis. Primers used for sequence analysis are
available on request.
Mutation validation
Novel variants that were not identified in previous studies
of NPHS2 were studied for their frequency in a cohort of
362 non-diseased Caucasian HapMap CEPH control alle-
les and, when possible, co-segregation with disease in the
respective families. In both instances, genotyping was per-
formed using MALDI-TOF mass spectroscopy based SNP
genotyping (Sequenom) at the Harvard Partners Genotyp-
ing Facility. Large control cohorts with no known kidney
disease from other ethnic groups were not necessary in
this study, as most of the patients in whom we identified
novel mutations were Caucasian. Only one sample was
non-Caucasian, and control samples from this ethnic
group (Sri-Lanken) was not available.
Genotyping of p.R229Q and p.A242V
One thousand nine hundred and eighty eight diabetic
samples from 3 distinct study groups with either type 1 or
type 2 diabetes were genotyped for the p.R229Q variant
using either an p.R229Q TaqMan allelic discrimination
assay, the MALDI-TOF mass spectroscopy Sequenom
based SNP genotyping at the Harvard Partners Genotyp-
ing Facility or Cla I digestion of exon 5 NPHS2 amplicons.
We designed a TaqMan allelic discrimination assay that
used a specific fluorescent, dye-labeled probe for both the
wild type (G755G) and mutant p.R229Q (G755A) alleles.
The sequences of the probes and primers were: wildtype
probe (Allele G) AGGGATCGATGTGCT-VIC dye at the 5'
end and MGB quencher at the 3' end, mutant probe
(Allele A) TGAGGGATTGATGTGC-FAM at the 5' end and
MGB quencher at the 3' end, forward primer AATTCCTT-
GTGCAAACCACTATGAA, reverse primer CGATGCTCT-
TCCTCTCTAGAAGAATTT. A 25 μL reaction was prepared
for each sample analyzed, containing 12.5 μL of TaqMan
Universal PCR Master Mix containing AmpliTaq Gold
DNA polymerase and other reagents (Applied Biosystems,
Foster City, CA, USA), 9.5 μL of DNase, RNase and Pro-
tease free Molecular grade water (Cellgro, Lawrence, KS,
USA), 0.5 μL of 100 pmole concentration of forward and
reverse primers (Applied Biosystems, Foster City, CA,
USA), 0.0625 μL of 100 uM concentration of Allele G and
Allele A Taqman MGB probes (Applied Biosystems, Foster
City, CA, USA) and 2.5 μL of 25 ng total genomic DNA or
p.R229Q plasmid DNA. Controls for this assay consisted
of non-template controls (NTC), 3 FSGS patients and 1
sibling from each of these subjects, that either have or
were not shown to have p.R229Q in a heterozygous state
from prior studies respectively [6]), and an p.R229Q plas-
mid (homozygous control). Genotyping was performed
in an Applied Biosystems 7300/7500 Real-Time PCR
machine (Applied Biosystems, Foster City, CA, USA).
All 429 samples from the Australian endocrine diabetics
were examined for p.R229Q using Cla1 digestion [6] and
further verified using direct sequencing performed with
the ABI Prism Big Dye Terminator Cycle Sequencing-ready
reaction kit (PE Applied Biosystems) by the Australian
Genome Research Facility using a Perkin-Elmer 377 auto-
mated sequencer.
Nurses' Health Study Group
Samples from either the Nurses' Health Study I or II were
genotyped for p.A242V or p.R229Q using a MALDI-TOF
mass spectroscopy Sequenom based SNP genotyping
assay developed and performed at the Harvard Partners
Genotyping Facility. Four Caucasian controls (CEPH)
samples from the international HapMap project without
at least one p.R229Q or p.A242V allele were genotyped at
the same time as the patient samples, and these were con-
sistently negative for both the c.686G>A and c.725C>T of
p.R229Q and p.A242V respectively. These variants do not
exist in public SNP databases nor are they present on cur-
rent Affymetrix genotyping SNP panels to our knowledge.
Statistics
The frequency distributions of alleles was assessed using
StatView for Windows, version 5.0 and SAS version 9.0.
Results
Sequence analysis of NPHS2: non-synonymous variants
We directly sequenced the entire coding region of the
NPHS2 gene in PCR amplified DNA from 371 individu-
als, 122 of whom also had at least 1 relative with FSGS.
We identified fifteen alleles that changed the predictedPage 3 of 10
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ples screened). These were either missense (p.R10T
(c.29G>C), p.V127W (c.379G>T), p.R138Q (c.413G>A),
p.V180M (c.538G>A), p.R229Q (c.686G>A), p.T232I
(c.694C>T), p.E237Q (c.709G>C), p.A242V (c.725 C>T),
p.L270F (c.810G>T), p.A284V (c.851C>T), p.L312V
(c.934C>G) and p.L327F (c.1048C>T), truncation
(p.Q215X (c.643C>T) or frameshift variants (397delA
and 855-856delAA) (Table 1). Twelve of these 63 patients
had non-synonymous variants in two alleles; 3 were
homozygous for p.V127W, p.R138Q or p.V180M, and the
remaining 9 were compound heterozygous for p.R138Q
and/or p.R229Q and a variety of other alleles (Table 2).
Homozygous non-synonymous and compound 
heterozygous variants
In 3 of the 122 families studied (2.5%), the p.R138Q,
p.V127W and p.V180M alleles were demonstrated in a
homozygous state (Table 2). In families with multiple
affected individuals available for genetic analysis, these
alleles segregated in a pattern consistent with autosomal
recessive transmission. We identified 9 compound heter-
ozygous events. A majority (7/9 or 78%) of these con-
sisted of p.R229Q, inherited together either with a rarer
allele (n = 4), p.R138Q (n = 2) or p.A284V (n = 3). These
mutations were identified in 2 index cases with a family
history of disease and 7 sporadic cases (Table 2). In the
proband's family, the alleles segregated with disease in an
autosomal recessive manner. In addition, we identified
p.R229Q and p.A242V in homozygous and compound
heterozygous states. The p.R229Q and p.A242V
homozygous events were identified in two unrelated spo-
radic patients (CPMC-96 and FG-GC-1112 respectively),
and the p.R229Q/p.A242V compound heterozygous state
was found in another unrelated sporadic patient (CH-1).
The p.R10T, p.V127W, p.Q215X and p.L270F alleles
(present in a compound heterozygous state with either
p.R138Q or p.R229Q (Table 2)) were not observed in 362
non-diseased control alleles. Only 1 proband with 2 dele-
terious NPHS2 alleles other than p.R229Q developed dis-
ease in adulthood (Table 2). The 4 other probands with
adult onset disease and significant NPHS2 variants in
both alleles had one p.R229Q variant. This supports the
notion that in the absence of a p.R229Q NPHS2 variant,
NPHS2 defects are unlikely to be the cause of disease in an
adult with FSGS undergoing genetic analysis.
Table 1: Non-synonymous NPHS2 variants detected
Type of variant Nucleotide 
change
Effect on coding 
sequence
Exon Heterozygous 
(n, %)
Homozygous 
(n, %)
Frequency in 
Familial FSGS
Frequency in 
Sporadic FSGS
missense c.29G>C p.R10T 1 1, 0.27% - N = 0 N = 1 
(1/249, 0.4%)
c.379G>T p.V127W 2 - 1, 0.27% N = 0 N = 1 
(1/249, 0.4%)
c.413G>A p.R138Q 3 5, 1.3% 1, 0.27% N = 5 (5/122, 4%) N = 1 
(1/249, 0.4%)
c.538G>A p.V180M 5 - 1, 0.27% N = 1 
(1/122, 0.8%)
N = 0
c.643C>T p.Q215X 5 1, 0.27% - N = 1 
(1/122, 0.8%)
N = 0
c.686G>A p.R229Q 5 40, 10.8% 1, 0.27% N = 10 
(10/122, 8.2%)
N = 31 
(31/249, 12.5%)
c.694C>T p.T232I 5 1, 0.27% - N = 0 N = 1 
(1/249, 0.4%)
c.709G>C p.E237Q 5 1, 0.27% - N = 0 N = 1 
(1/249, 0.4%)
c.725C>T p.A242V 5 14, 3.7% 1, 0.27% N = 1 
(1/122, 0.8%)
N = 14 
(14/249, 5.6%)
c.810G>T p.L270F 6 1, 0.27% - N = 0 N = 1 
(1/249, 0.4%)
c.851C>T p.A284V 7 2, 0.5% 1, 0.27% N = 0 N = 3 
(3/249, 1.2%)
c.934C>G p.L312V 8 1, 0.27% - N = 1 
(1/122, 0.8%)
N = 0
c.1048C>T p.L327F 8 1, 0.27% - N = 0 N = 1 
(1/249, 0.4%)
Frame-shift 397delA Frame-shift 3 1, 0.27% - N = 0 N = 1 
(1/249, 0.4%)
855/6delAA Frame-shift 7 1, 0.27% - N = 0 N = 1 
(1/249, 0.4%)Page 4 of 10
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Fifty-one patients had a single heterozygous NPHS2 allele
predicted to alter the encoded protein. These variants (and
the respective number of patients they were demonstrated
in) were: p.R138Q (n = 3), p.R229Q (n = 32), p. T232I (n
= 1), p.E237Q (n = 1), p.A242V (n = 13) and p.L312V (n
= 1). Both the p.T232I (c.694C>T) and p.L312V
(c.934C>G) alleles were absent in 362 non-diseased con-
trol alleles sequenced, while all the others have been dem-
onstrated by previous studies [6-8,12-24]. The p.T232I
variant was identified in an 8 year-old African-American
boy (UAB-023) with no family history who developed
FSGS at the age of 2.5 years. The p.L312V mutation was
identified in 2 of 4 siblings in a heterozygous state, both
of whom had biopsy-confirmed FSGS (Family FG-DK).
No second mutant allele was found. Both parents were
deceased, the father from kidney failure secondary to
prostrate cancer and the mother for unknown reasons.
Genotyping of p.R229Q and p.A242V in women enrolled in 
the Nurses' Health Study
The p.R229Q and p.A242V variants were the most com-
mon non-synonymous variants demonstrated in our
FSGS patient cohort (with allele frequencies of 0.02 and
0.06 respectively). The frequency of p.R229Q did not dif-
fer between the FSGS races studied, whereas the p.A242V
variant was present in a higher proportion of African
Americans with FSGS compared to other races (chi-square
with Yates correction 9.79, p = 0.00057). We were inter-
ested in whether both the p.R229Q and p.A242V variants
might contribute to the risk of renal impairment in the
general population by investigating whether these vari-
ants associate with increased urinary albumin/creatinine
ratio, an early marker of renal disease.
We genotyped the p.R229Q variant in a cohort of 2,596
women aged over 50 years who were enrolled in 1976 to
participate in the Nurses' Health Study I (of which 97%
were of Western european descent). We genotyped the
p.A242V variant in 1559 participants in the Nurses'
Health Study II (age 44 or greater; 94% of Western euro-
pean descent). The allele frequencies of the p.R229Q and
p.A242V variants in these cohorts were 0.0352 and 0.034,
respectively. The genotype frequencies of p.R229Q and
p.A242V heterozygotes were 6.5% and 7.0% respectively.
Homozygous events were rare for both variants, with gen-
otype frequencies of 0.1% and 0.26% (for p.R229Q and
p.A242V respectively). We observed no association
Table 2: Clinical characteristics of patients with homozygous and compound heterozygous non-synonymous NPHS2 variants
Proband 
screened
Ethnicity Homozygous or
Compound 
heterozygous
Previously 
published as 
disease causing
Affected family 
members
Age of onset 
(years)
Response to 
immunosuppressive 
treatment
Tx/
Recurrence
FG-HU-11S Sri-Lanken p.V127W/
p.V127W
No FG-HU-11 4 NA NA
FG-FW-12 F Caucasian p.R138Q/
p.R138Q
[8,12-15,17,18] FG-FW-12
FG-FW-11
FG-FW-13
FG-FW-14
4
8
4
2
No
No
No
No
Yes/No
Yes/No
Yes/No
No
FG-HN-11F Caucasian p.R138Q/
p.Q215X
No FG-HN-11
FG-HN-111
8
1.08
No
No
Yes/No
No
FG-EJ-2112F Caucasian p.R138Q/
p.R229Q
[6] FG-EJ-2112
FG-EJ-2115
FG-EJ-2116
5
3
3
NA
No
No
No
Yes/Yes
Yes/Yes
FG-IV-11F* Caucasian/
Lebanese
p.V180M/
p.V180M
[12] FG-IV-11
FG-IV-12
14
17
Partial
NA
No
NA
UNC-530S NA p.R229Q/
p.R10T
No UNC-530 18 NA NA
CPMC-93S Caucasian p.R229Q/
p.L270F
No CPMC-93 38 Partial NA
FG-HP-11S Hispanic p.R229Q/
p.A284V
[8,15,17,19] FG-HP-11
FG-HP-12
17
NA
No
No
No
Yes/No
CPMC-2S Hispanic p.R229Q/
p.A284V
[8,15,17,19] CPMC-2 21 NA NA
CPMC-6S Caucasian p.R229Q/
p.A284V
[8,15,17,19] CPMC-6 27 NA NA
ST-11S Caucasian p.R229Q/
p.L327F
[6] ST-11 3 No NA
CPMC-28S Caucasian 397delA/855/
6delAA
No CPMC-28 27 No NA
F; individual with at least one other affected family member with FSGS or proteinuria, F*; individual with at least one other affected family member 
from a consanguineous marriage with FSGS or proteinuria, S; patient without a family history of FSGS NA; data not available.Page 5 of 10
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of the homozygous or heterozygous states with increased
urinary albumin/creatinine ratio.
Association studies of p.R229Q with diabetic nephropathy
We were also interested in investigating whether p.R229Q
might represent a modifying allele for renal disease in a
more common cause of renal impairment, diabetic neph-
ropathy. The p.R229Q variant has been associated with
microalbuminuric events (designated by semi quantita-
tive protocol) in an urban population isolated from Brazil
[25] and has shown to cause FSGS in the compound het-
erozygous state along with rarer non-synonymous vari-
ants [6]. We genotyped p.R229Q in 1988 diabetic patients
from 3 different cohorts and investigated for associations
between p.R229Q with end-stage renal disease and pro-
teinuria (Table 3).
Utah diabetics
Two hundred and eighty patients with either type 1 diabe-
tes (n = 41, 15%) or type 2 diabetes (n = 239, 85%) were
studied. Twenty patients (49%) with type 1 diabetes and
89 patients (37%) with type 2 diabetes had end-stage
renal disease. Diabetic patients without end-stage renal
disease were used as controls (21/41, 51% of type 1 dia-
betics; 150/239, 63% of type 2 diabetics). The allele fre-
quency of R229Q in the diabetic cases with end-stage
renal disease was 0.036, and 0.030 in the controls without
ESRD (Table 3). No associations between p.R229Q and
end-stage renal disease in either type 1 or type 2 diabetes
were found (chi-square 3.39 and 0.121 with p values of
0.07 and 0.73 respectively).
GoKinD samples
One thousand two hundred and seventy-nine patients
with 10 or more years of type 1 diabetes from the Genetics
of Kidney Disease in Diabetes (GoKinD) were genotyped
for p.R229Q. Four hundred and fifty-five of these subjects
were "case" samples with end-stage renal disease, while
the remaining 824 without end-stage renal disease served
as "control" subjects. p.R229Q was found to have an over-
all allele frequency of 0.04 in the entire set of GoKinD
samples. The allele frequency of the variant in "cases" with
end-stage renal disease was 0.0297 and 0.039 in the con-
trol type 1 diabetics without nephropathy. There was no
association between p.R229Q in the heterozygous state
and proteinuria or end-stage renal disease in the case dia-
betics compared to normoalbuminuric control diabetics
(chi-square 1.68, p = 0.20). In addition, the presence of a
p.R229Q allele was not seen at greater frequency in sub-
jects with elevated creatinine. p.R229Q Heterozygous
individuals also did not have a higher incidence of abnor-
mal creatinine (chi-square 1.314, p = 0.252) than individ-
uals lacking this variant.
Renal disease is an established risk factor for cardiovascu-
lar disease [26]. p.R229Q was not seen at greater fre-
quency in individuals with cardiovascular complications
(chi-square 0.21 p = 0.65), hypertension (chi-square 1.31,
p = 0.25), nor with subjects taking an angiotensin convert-
ing enzyme inhibitor (ACEi), or other antihypertensive
medications (chi-square 0.002 and 0.99 with correspond-
ing p values of 0.97 and 0.32).
Table 3: End-stage renal disease and albuminuria associations with p.R229Q in different diabetic cohorts
N = 280 Type I (n = 41) Type 2 (n = 239) Total (n = 280)
Utah diabetes study No ESRD
(n = 171)
21 p.R229R 0 p.R229Q 140 p.R229R 10 p.R229Q 161 p.R229R 10 p.R229Q
ESRD
(n = 109)
17 p.R229R 3 p.R229Q
(χ2 3.40, p = 0.07)
82 p.R229R 7 p.R229Q (2%)
(χ2 0.12, p = 0.73)
99 p.R229R 10 p.R229Q (2%)
(χ2 1.11, p = 0.29)
N = 1,279 Type I (n = 1,279) Type 2 - Total -
GoKinD No ESRD
(n = 824)
759 p.R229R 65 p.R229Q - - - -
ESRD
(n = 455)
428 p.R229R p.27 R229Q
(χ2 1.68, p = 0.20)
- - - -
N = 429 Type I (n = 67) Type 2 (n = 357) Total (n = 429)
Australian endocrine Normo
(n = 279)
47 p.R229R 4 p.R229Q 206 p.R229R 22 p.R229Q 253 p.R229R 26 p.R229Q
Micro
(n = 93)
8 p.R229R 2 p.R229Q
(χ2 1.39, p = 0.24)
77 p.R229R 6 p.R229Q (2%)
(χ2 0.44, p = 0.51)
85 p.R229R 8 p.R229Q (2%)
(χ2 0.04, p = 0.84)
Macro
(n = 52)
6 p.R229R 0 p.R229Q
(χ2 0.5, p = 0.48)
42 p.R229R 4 p.R229Q (2%)
(χ2 0.04, p = 0.84)
48 p.R229R 4 p.R229Q (2%)
(χ2 0.14, p = 0.71)
Micro- or Macro
(n = 145)
14 p.R229R 2 p.R229Q
(χ2 0.32, p = 0.57)
119 p.R229R 10 p.R229Q (2%)
(χ2 0.36, p = 0.55)
133 p.R229R 12 p.R229Q (2%)
(χ2 0.13, p = 0.72)
The frequency of p.R229Q in patients with type 1 or type 2 diabetes with end-stage renal disease (ESRD) was compared to those without for the 
Utah diabetes study and Genetics of Kidney Disease in Diabetes (GoKinD) participants. Likewise, the frequency of p.R229Q in patients with 
microalbuminuria (Micro) or macroalbuminuria (Macro) was compared with the frequency of normoalbuminuria (Normo) in patients with type 1 or 
type 2 diabetes in the Australian endocrine patients. No associations were found.Page 6 of 10
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these were excluded from all our association studies. The
homozygotes with p.R229Q had a 2.15 fold increase of
developing proteinuria or ESRD but this did not reach sta-
tistical significance. This may be due to the very small
number of subjects having this homozygous genotype
(95% confidence interval 0.19–24.1), or it may be due to
chance.
Australian endocrine diabetics
Four hundred and twenty-four patients with median dia-
betes duration of 20 years (range 3-to-58 years) enrolled
through the Australian endocrine diabetes study were also
studied. Sixty-seven had type 1 diabetes (51 with an uri-
nary albumin excretion rate (AER) <20 μg/min, 10 with
an AER between 20 μg/min and 200 μg/min, and the
remaining 6 with an AER >20 μg/min) and the remaining
357 had type 2 diabetes (228 with an AER<20 μg/min, 83
with an AER between 20 μg/min and 200 μg/min, and the
remaining 46 with an AER >200 μg/min). The p.R229Q
variant had an allele frequency of 0.044 in the Australian
endocrine diabetics. The allele frequency in cases with
"nephropathy" (defined by an AER >20 μg/min) was
0.041 and 0.047 in the controls (subjects with an AER <20
μg/min) (Table 3). p R229Q did not associate with "neph-
ropathy" (defined by an AER >20 μg/min) in the Austral-
ian endocrine diabetics (chi-square= 0.13, p = 0.72),
micro or macroalbuminuria in type 1 diabetes (chi-square
1.39 and 0.5 with p values of 0.24 and 0.48 respectively),
nor did it associate with micro or macroalbumiuria in
type 2 diabetes (chi-square 0.44 and 0.04 with p values of
0.51 and 0.84 respectively).
No association between "diabetic nephropathy" and p.R229Q
When we pool the results from all 3 cohorts together and
define a "case" diabetic as one with end-stage renal dis-
ease or abnormal proteinuria and a "control" as having no
end-stage renal disease and normal urinary protein, no
associations are present between p.R229Q and "diabetic
nephropathy" (chi-square 0.67 and p value of 0.41).
Discussion
We resequenced the coding sequence of NPHS2 in 371
individuals with FSGS and a median age of onset of dis-
ease of 25 years and found that 63 (or 17%) of the
patients have at least one allele that alters the NPHS2 cod-
ing sequence, and of these, 12 (or 3.2% of the 371
screened) had these events in both NPHS2 alleles. Likely
disease-causing mutations (homozygous or compound
heterozygous) were identified in 4% (5/122) of the fami-
lies and 2.8% (7/249) of the sporadics (excluding the
homozygous and compound heterozygous events of
p.R229Q and/or p.A242V).
We previously screened 30 multiplex families for NPHS2
mutations with adolescent or adult onset FSGS and iden-
tified 7 (23%) homozygous (n = 1) or compound hetero-
zygous (n = 6) patients [6]. When these families are added
to those screened here, we have identified likely disease-
causing mutations in 8% of families (12 of 154 families).
Our data show a non-trivial frequency of homozygous or
compound heterozygous alleles in NPHS2 in late onset
FSGS-affected individuals. Such genotypes are more fre-
quent in patients with at least 1 other affected family
member compared to sporadic FSGS patients (8% vs 2.8%
respectively). These percentages are significantly smaller
than most of the previous large studies which have
focused on pediatric disease [15,17]. Several of the novel
mutations identified in this study that both lead to amino
acid substitutions and are present in the compound heter-
ozygous state, with other previously known variants, are
predicted to affect protein function of podocin using two
SNP prediction algorithms; Sorting Intolerant From Toler-
ant (SIFT) and Polymorphism Phenotyping (PolyPhen).
The p.R10T variant is predicted to be tolerated by SIFT and
benign using Polyphen, p.V127W is predicted to be not
tolerated by SIFT and possibly damaging by PolyPhen and
p.L270F is predicted to be not tolerated by SIFT and pos-
sibly damaging using PolyPhen.
The finding of mutant NPHS2 alleles in sporadic cases
confirms that disease that appears to be sporadic may in
fact be inherited as a result of inheritance of mutant alleles
from both parents, even in the absence of a positive family
history of disease [27]. This may mean that homozygous
or compound heterozygous events in other not-yet-iden-
tified genes that cause FSGS by recessive inheritance may
underlie disease in these patients.
The contribution of rare alleles to FSGS
We identified 51 patients (51/371, 14%) that had a heter-
ozygous allele that altered the amino acid sequence with-
out any other identified NPHS2 allele. The majority of
these were the p.R229Q and p.A242V alleles (Table 1).
Two of these alleles (p.T232I (c.694C>T) and p.L312V
(c.934C>G)) are private non-conservative alleles that
have not been identified in previous NPHS2 resequencing
studies. The contribution of these rare alleles to disease is
unclear. Neither was observed in any of the control alleles
genotyped. The p.T232I allele was demonstrated in a sub-
ject with sporadic disease. The p.L312V allele was present
in all affected siblings in a family with biopsy-confirmed
FSGS. We cannot out rule the possibility of autosomal
dominant disease in this family, as the father reportedly
died from kidney impairment secondary to prostate can-
cer and the mother died of unknown causes. Interestingly,
the p.T232I variant is predicted to be not tolerated by SIFT
and possibly damaging by PolyPhen, and p.L327V is tol-
erated by SIFT and benign using PolyPhen. Rare hetero-Page 7 of 10
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function, but these will need to be studied in cell culture
to verify this.
Rare NPHS2 alleles have also been demonstrated in sub-
jects with thin basement membrane nephropathy
(TBMN). Tonna et al. 2003 identified a rare heterozygous
variant (p.R224H (c.672G>A)) in only one patient with
both TBMN and proteinuria, and like p.T232I the allele
was not demonstrated in any control sample [28]. With-
out knowing the frequency with which non-proteinuric
control groups carry single, rare, non-synonymous vari-
ants, it is difficult to know the clinical significance of such
variants.
A small number of studies have attempted to show that
heterozygous mutations in both the NPHS2 and NPHS1
genes in a single patient can cause FSGS [7,8,16]. It is
unclear, however, what the frequency of such digenic
events is in non-proteinuric (control) individuals. It is a
straightforward hypothesis that digenic or perhaps even
trigenic combinations of non-synonymous variants may
occur in either of the NPHS2, ACTN4, TRPC6, CD2AP, or
even PLCE1 genes in FSGS patients (especially those with
sporadic disease). This may be in fact be the case in some
of these patients with a single non-synonymous NPHS2
allele (especially if the allele is rare or is known to cause
disease in the homozygous or compound heterozygous
state), but confirming such a hypothesis will require
extensive resequencing of many genes in FSGS cases as
well as controls. It is however clear that 2.8% of patients
with late onset, non-familial, FSGS have disease attributa-
ble to two mutant NPHS2 alleles.
Common non-synonymous variants: the p.R229Q and 
p.A242V alleles
The most common non-synonymous changes we identi-
fied were the p.R229Q and p.A242V variants with popu-
lation frequencies of 0.02 and 0.06, respectively, in the
FSGS probands. We found one FSGS patient homozygous
for p.R229Q, one homozygous for p.A242V, and one with
compound heterozygosity for each of these alleles. Weber
et al identified 3 families (2 of which are consanguineous)
and 2 sporadic cases of FSGS with homozygosity for
p.R229Q, [17]. This substitution is one of the most com-
monly reported NPHS2 alleles [6,8,14,15,20,21,25] with
a greater frequency in Europeans (0.036) compared to the
frequency in African Americans and Brazilians [6,17,25].
In another study, p.R229Q heterozygotes were found to
have a 2.77 fold increased risk of developing microalbu-
minuria compared with controls [25], but it has been
unclear whether this allele represents a genetic modifier
for renal impairment in other diseases such as diabetic
nephropathy.
To clarify whether these common non-synonymous vari-
ants cause or contribute to the development of albuminu-
ria, we genotyped both of these alleles in cohorts of
women from the Nurses' Health Study I and II. We
observed that neither the p.R229Q nor the p.A242V allele
were associated with increases in urine albumin/creati-
nine ratio in either the homozygous or heterozygous
states. We found that p.A242V was present in an allele fre-
quency of 0.034 in the Nurses' Health Study II, but in only
0.02 in the FSGS cohort. We note that this frequency in
the control group (NHSII) is higher than that previously
reported in control groups of similar ethnicity [29]. In the
FSGS sample set, this variant was present in a higher fre-
quency in persons of African descent compared to other
ethnicities (chi-square with Yates correction 9.79, p =
0.00057), consistent with other studies [17]). It is not
clear how the p.R229Q allele causes FSGS in the com-
pound heterozygote state when inherited together with a
second mutant allele [6,8,14-17,19,22], but not in the
homozygous state, but this study confirms earlier suspi-
cion that p.R229Q causes disease only in conjunction
with a second more detrimental allele [6]. An earlier study
reported that p.R229Q associates with microalbuminuric
events in the population [25]. However, in the present
study, we saw no association of the p.R229Q allele with
albuminuria in either the Nurses' Health Study I nor in
the diabetic populations analyzed. Further, the p.R229Q
and p.A242V alleles in the homozygous state do not cause
FSGS. The results of the genotyping of p.R229Q and
p.A242V in the Nurses' Health Study reinforces the impor-
tance of evaluating potentially pathogenic variants in
large populations.
Pathogenicity of NPHS2 mutations
The biological effect of twelve mutant NPHS2 alleles
(p.P118L, p.R138Q, p.R138X, p.D160G, p.R168H,
p.R168C, p.R168S, p.V180M, p.R238S, DelLER (aa 237–
239), p.V260E, and p.R291W) and two relatively com-
mon variants (p.P20L and p.G92C) have been studied in
cell culture [30-32]. All but two of the mutants (p.V180M
and p.R238S) fail to reach the plasma membrane in con-
trast to wild type podocin, whereas both the p.P20L and
p.G92C variants do reach the plasma membrane. The lack
of proper targeting of mutant NPHS2 to the plasma mem-
brane has been shown to affect nephrin trafficking [30-
32]. Other variants may have less avid binding to nephrin,
as has been demonstrated in the case of p.R229Q [6].
However, lacking a systematic study of the frequency and
biological effects of non-synonymous variants, it remains
unclear which altered functions are meaningful markers
of clinical pathogenicity.
Conclusion
Mutations in NPHS2 are a rare cause of FSGS of late onset.
Most (but not all) individuals with adult onset FSGSPage 8 of 10
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allele. Our findings are consistent with other recent
reports [9,10]. We have demonstrated that NPHS2 muta-
tions contribute to FSGS in 8% of the familial cases and
2.8% of the sporadic cases analyzed here. Furthermore,
the most commonly found polymorphisms demonstrated
in NPHS2 resequencing, p.R229Q and p.A242V, do not
appear to cause FSGS, nor associate with proteinuria in
the homozygous or heterozygous state. In addition,
p.R229Q heterozygous events do not associate with meas-
ures of kidney dysfunction in diabetic individuals, and
thus p.R229Q is unlikely to represent a major genetic
modifier for proteinuria.
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